Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
AstraZeneca
Shannon N Westin; Kathleen Moore; Hye Sook Chon; Jung-Yun Lee; Jessica Thomes Pepin; Michael Sundborg; Ayelet Shai; Joseph de la Garza; Shin Nishio; Michael A Gold; Ke Wang; Kristi McIntyre; Todd D Tillmanns; Stephanie V Blank; Ji-Hong Liu; Michael McCollum; Fernando Contreras Mejia; Tadaaki Nishikawa; Kathryn Pennington; Zoltan Novak; Andreia Cristina De Melo; Jalid Sehouli; Dagmara Klasa-Mazurkiewicz; Christos Papadimitriou; Marta Gil-Martin; Birute Brasiuniene; Conor Donnelly; Paula Michelle Del Rosario; Xiaochun Liu; Els Van Nieuwenhuysen; DUO-E Investigators
Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.